ReviewCells2026
Candidate Spatial Niches Associated with Gastric Cancer Metastasis and Treatment Resistance: Functional Classification, Evidence Boundaries, and a Translational Framework.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Gastric cancer metastasis and poor treatment responses are spatially heterogeneous; however, single-marker positivity, cellular enrichment, or simple colocalization alone is insufficient to establish a functionally meaningful spatial niche. Within this framework, "treatment resistance" encompasses primary nonresponse, reduced treatment sensitivity, insufficient local drug delivery, post-treatment residual survival, acquired resistance, and interlesional differences in therapeutic efficacy. We propose a minimum criteria chain for candidate spatial niches comprising four elements: a specified spatial context; neighborhoods characterized using prespecified and transparently reported spatial rules; local functional programs concordant with these neighborhoods; and associations with malignant phenotypes or clinical outcomes. Based on the principle of linking dominant spatial contexts with their predominant malignant functional outputs, we summarize four candidate niches within primary tumors-the invasive front-tumor-stroma interface, immune exclusion-immune evasion, hypoxia-metabolic adaptation, and perivascular supportive niches-as well as an organ-context-dependent adaptive niche-forming process at metastatic sites. The level of evidence supporting these categories varies substantially. Immune-exclusion-related spatial states currently have relatively stronger links to treatment-response cohorts; however, rigorous gastric-cancer-specific in situ validation remains limited, and no candidate niche has yet achieved full clinical validation. Invasive-front and hypoxic niches are supported primarily by pathological or mechanistic evidence, whereas evidence for perivascular niches remains limited despite emerging longitudinal treatment-response observations, and metastatic niches outside the peritoneum require stronger longitudinal, local functional, and spatial-perturbation validation. This framework aims to standardize spatial-niche terminology and evidence interpretation and guide future quantification, validation, and potential clinical translation in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.